T cell responses are still robust against the variant in most individuals with prior SARS-CoV-2 infection or vaccination, despite low antibody responses, finds a study.

This also provides protection against severe disease, said researchers at the Massachusetts General Hospital (MGH).

When an individual is infected with the Covid-19 causing virus SARS-CoV-2, the immune system is called into action to produce antibodies and T cells that target viral proteins and clear the infection.

It has become clear that the recent Omicron variant of SARS-CoV-2 can unfortunately escape antibody responses even in many people who have been vaccinated against Covid-19.

But the new research published in the journal Cell showed that T cell responses in individuals with prior infection, vaccination, both prior infection and vaccination, and booster vaccination were largely preserved against the Omicron spike protein.

Individuals with prior infection also had responses against other proteins in the virus.

For the study, the team obtained blood samples from 76 vaccinated and unvaccinated adults with and without prior SARS-CoV-2 infection.

“We found that T cells from most individuals retained their recognition of Omicron even when antibodies did not. This is good news,” said co-lead author Anusha Nathan, a medical student working at the Ragon Institute of MGH, MIT and Harvard.

Approximately 20 per cent of individuals had significantly reduced T cell responses despite prior infection or vaccination, however, and certain genetic characteristics were linked with this poor response.

But, booster vaccination appeared to enhance T cell responses by 20-fold, the researchers found.

“Our findings should provide some reassurance to the general population that the vast majority of prior infected and vaccinated individuals should have a T cell response to Omicron that gives protection against severe Covid-19,” said senior author Gaurav D. Gaiha, a gastroenterologist at MGH.

“However, similar to antibody studies, our study also provides further impetus for people to get booster vaccines to help protect against Omicron by substantially increasing their T cell immunity,” he added.

The scientists noted that their discovery that some people have lower responses to Omicron may indicate that the virus can evolve to escape even T cells.

“So, we have to continue to work on vaccines that may be resistant to future variants and keep taking sensible precautions like keeping up to date on vaccination, mask-wearing and testing appropriately to protect ourselves and our communities,” said co-lead author Vivek Naranbhai, a hematology/oncology fellow at MGH and Dana-Farber Cancer Institute.

–IANS

rvt/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor